Thalidomide Combined With Chemotherapy in the Treatment of Relapsed or Refractory Yolk Sac Tumor

Inclusion criteria

• ✓. The child must have histological evidence of an extracranial malignant germ cell tumor (vitelline sac tumor).
• ✓. Children must be no more than 18 years old at the time of study participation.
• ✓. The patients were children with vitelline cystic tumor who were resistant to drugs after at least two platinum-containing chemotherapy regimes or whose disease recurred within 3 months after chemotherapy regimes, or who recurred again or repeatedly after treatment with Sirolimus combined with TIC chemotherapy regimes.
• ✓. The child must have measurable lesions (recorded according to RECIST criteria) or non-evaluable disease with tumor marker AFP greater than 5 times the upper limit of normal.
• ✓. Lansky performance status score ≥50.
• ✓. The life expectancy of the child must exceed 6 weeks.
• ✓. The child must have recovered from the response to all previous anticancer treatments.
• ✓. No serious organ dysfunction: normal cardiac function (ejection fraction \> 50% or BNP \< 2000pg/ml); Liver function: alanine aminotransferase increased less than 5 times the upper limit of normal, bilirubin increased less than 3 times the upper limit of normal; Renal function: creatinine and urea nitrogen levels below the normal range; The white blood cells were greater than 3×109/L, and the platelets were greater than 100×109/L.